Therapeutic approaches to target alpha-synuclein pathology

[1]  T. Südhof,et al.  Cell Biology and Pathophysiology of α-Synuclein. , 2018, Cold Spring Harbor perspectives in medicine.

[2]  V. Lee,et al.  Distinct α-Synuclein strains and implications for heterogeneity among α-Synucleinopathies , 2018, Neurobiology of Disease.

[3]  Susmit B. Sambhare,et al.  A Bacteriophage Capsid Protein Is an Inhibitor of a Conserved Transcription Terminator of Various Bacterial Pathogens , 2017, Journal of bacteriology.

[4]  D. Wesson,et al.  The olfactory bulb as the entry site for prion-like propagation in neurodegenerative diseases , 2016, Neurobiology of Disease.

[5]  T. Dawson,et al.  c-Abl and Parkinson’s Disease: Mechanisms and Therapeutic Potential , 2017, Journal of Parkinson's disease.

[6]  David S. Park,et al.  β2-Adrenoreceptor is a regulator of the α-synuclein gene driving risk of Parkinson’s disease , 2017, Science.

[7]  D. Selkoe,et al.  A user's guide for α‐synuclein biomarker studies in biological fluids: Perianalytical considerations , 2017, Movement disorders : official journal of the Movement Disorder Society.

[8]  L. Defebvre,et al.  New perspectives on study designs for evaluating neuroprotection in Parkinson's disease , 2017, Movement Disorders.

[9]  S. Mallal,et al.  T cells of Parkinson’s disease patients recognize α–synuclein peptides , 2017, Nature.

[10]  V. Gradinaru,et al.  Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems , 2017, Nature Neuroscience.

[11]  S. Chandra,et al.  The Role of Co-chaperones in Synaptic Proteostasis and Neurodegenerative Disease , 2017, Front. Neurosci..

[12]  G. Coetzee,et al.  Parkinson's disease-associated genetic variation is linked to quantitative expression of inflammatory genes , 2017, PloS one.

[13]  P. Brundin,et al.  Solving the conundrum of insoluble protein aggregates , 2017, The Lancet Neurology.

[14]  C. Adler,et al.  The Systemic Synuclein Sampling Study: toward a biomarker for Parkinson's disease. , 2017, Biomarkers in medicine.

[15]  W. Ko,et al.  Oral ambroxol increases brain glucocerebrosidase activity in a nonhuman primate , 2017, Synapse.

[16]  H. Braak,et al.  Neuropathological Staging of Brain Pathology in Sporadic Parkinson’s disease: Separating the Wheat from the Chaff , 2017, Journal of Parkinson's disease.

[17]  C. Tanner,et al.  Biomarker‐driven phenotyping in Parkinson's disease: A translational missing link in disease‐modifying clinical trials , 2017, Movement disorders : official journal of the Movement Disorder Society.

[18]  K. Thorn,et al.  α-Synuclein Promotes Dilation of the Exocytotic Fusion Pore , 2017, Nature Neuroscience.

[19]  B. Mollenhauer,et al.  Development of a Biochemical Diagnosis of Parkinson Disease by Detection of &agr;-Synuclein Misfolded Aggregates in Cerebrospinal Fluid , 2017, JAMA neurology.

[20]  D. Krainc,et al.  α-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies , 2017, Nature Medicine.

[21]  A. Lang,et al.  Precision medicine for disease modification in Parkinson disease , 2017, Nature Reviews Neurology.

[22]  D. James Surmeier,et al.  Selective neuronal vulnerability in Parkinson disease , 2017, Nature Reviews Neuroscience.

[23]  L. Parnetti,et al.  Therapeutic potential of autophagy-enhancing agents in Parkinson’s disease , 2017, Molecular Neurodegeneration.

[24]  Jianhua Zhang,et al.  Trehalose does not improve neuronal survival on exposure to alpha-synuclein pre-formed fibrils , 2017, Redox biology.

[25]  M. Grundman,et al.  First‐in‐human assessment of PRX002, an anti–α‐synuclein monoclonal antibody, in healthy volunteers , 2016, Movement disorders : official journal of the Movement Disorder Society.

[26]  G. Sotiropoulou,et al.  KLK6 proteolysis is implicated in the turnover and uptake of extracellular alpha-synuclein species , 2016, Oncotarget.

[27]  P. Calabresi,et al.  Cerebrospinal Fluid b-Glucocerebrosidase Activity Is Reduced in Parkinson ’ s Disease Patients , 2017 .

[28]  M. Goedert,et al.  REVIEW ARTICLE Like prions: the propagation of aggregated tau and a -synuclein in neurodegeneration , 2017 .

[29]  C. Adler,et al.  The Search for a Peripheral Biopsy Indicator of &agr;-Synuclein Pathology for Parkinson Disease , 2017, Journal of neuropathology and experimental neurology.

[30]  J. Volkmann,et al.  Parkinson disease , 2017, Nature Reviews Disease Primers.

[31]  J. Kordower,et al.  Mitochondrial pyruvate carrier regulates autophagy, inflammation, and neurodegeneration in experimental models of Parkinson’s disease , 2016, Science Translational Medicine.

[32]  Yong-Xiang Chen,et al.  Phosphorylation induces distinct alpha-synuclein strain formation , 2016, Scientific Reports.

[33]  Daniela Berg,et al.  Advances in markers of prodromal Parkinson disease , 2016, Nature Reviews Neurology.

[34]  K. Wennerberg,et al.  c-Abl Inhibitors Enable Insights into the Pathophysiology and Neuroprotection in Parkinson’s Disease , 2016, Front. Aging Neurosci..

[35]  Ho Chul Kang,et al.  Pathological α-synuclein transmission initiated by binding lymphocyte-activation gene 3 , 2016, Science.

[36]  M. Ingelsson.  Alpha-Synuclein Oligomers—Neurotoxic Molecules in Parkinson's Disease and Other Lewy Body Disorders , 2016, Front. Neurosci..

[37]  M. Esiri,et al.  Alpha‐synuclein RT‐QuIC in the CSF of patients with alpha‐synucleinopathies , 2016, Annals of clinical and translational neurology.

[38]  John Q Trojanowski,et al.  Widespread transneuronal propagation of α-synucleinopathy triggered in olfactory bulb mimics prodromal Parkinson’s disease , 2016, The Journal of experimental medicine.

[39]  E. Masliah,et al.  Exposure to bacterial endotoxin generates a distinct strain of α-synuclein fibril , 2016, Scientific Reports.

[40]  Y. Shim,et al.  Anti-aging treatments slow propagation of synucleinopathy by restoring lysosomal function , 2016, Autophagy.

[41]  J. Kordower,et al.  How strong is the evidence that Parkinson's disease is a prion disorder? , 2016, Current opinion in neurology.

[42]  Simon G. Coetzee,et al.  Enrichment of risk SNPs in regulatory regions implicate diverse tissues in Parkinson’s disease etiology , 2016, Scientific Reports.

[43]  T. Sherer,et al.  Nilotinib – Differentiating the Hope from the Hype , 2016, Journal of Parkinson's disease.

[44]  Jaeil Ahn,et al.  Nilotinib Effects in Parkinson’s disease and Dementia with Lewy bodies , 2016, Journal of Parkinson's disease.

[45]  Dan Li,et al.  Versatile Structures of α-Synuclein , 2016, Front. Mol. Neurosci..

[46]  S. Hamilton-Dutoit,et al.  Pathological α‐synuclein in gastrointestinal tissues from prodromal Parkinson disease patients , 2016, Annals of neurology.

[47]  M. Biran,et al.  Mitochondrial pyruvate carrier in Trypanosoma brucei , 2016, Molecular microbiology.

[48]  Arthur W. Toga,et al.  CSF biomarkers associated with disease heterogeneity in early Parkinson’s disease: the Parkinson’s Progression Markers Initiative study , 2016, Acta Neuropathologica.

[49]  Abid Oueslati.  Implication of Alpha-Synuclein Phosphorylation at S129 in Synucleinopathies: What Have We Learned in the Last Decade? , 2016, Journal of Parkinson's disease.

[50]  A. Schapira,et al.  The relationship between glucocerebrosidase mutations and Parkinson disease , 2016, Journal of neurochemistry.

[51]  H. Braak,et al.  Review: Sporadic Parkinson's disease: development and distribution of α‐synuclein pathology , 2016, Neuropathology and applied neurobiology.

[52]  C. Manzoni,et al.  Is Alpha-Synuclein Loss-of-Function a Contributor to Parkinsonian Pathology? Evidence from Non-human Primates , 2016, Front. Neurosci..

[53]  Jiancheng Liu,et al.  Tet3 Reads 5-Carboxylcytosine through Its CXXC Domain and Is a Potential Guardian against Neurodegeneration. , 2016, Cell reports.

[54]  Takahiko Tokuda,et al.  Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson’s disease , 2016, Molecular Neurodegeneration.

[55]  C. Adler,et al.  Parkinson disease and incidental Lewy body disease , 2015, Neurology.

[56]  W. Poewe,et al.  The Concept of Prodromal Parkinson’s Disease , 2015, Journal of Parkinson's disease.

[57]  Jacqueline Burré.  The Synaptic Function of α-Synuclein , 2015, Journal of Parkinson's disease.

[58]  Nicolas Fritz,et al.  α‐synuclein assemblies sequester neuronal α3‐Na+/K+‐ATPase and impair Na+ gradient , 2015, The EMBO journal.

[59]  P. Brundin,et al.  Immunotherapy in Parkinson’s Disease: Micromanaging Alpha-Synuclein Aggregation , 2015, Journal of Parkinson's disease.

[60]  G. Petsko,et al.  Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations , 2015, The Lancet Neurology.

[61]  Victor Tapias,et al.  shRNA targeting α-synuclein prevents neurodegeneration in a Parkinson's disease model. , 2015, The Journal of clinical investigation.

[62]  M. Giugliano,et al.  α-Synuclein strains cause distinct synucleinopathies after local and systemic administration , 2015, Nature.

[63]  R. Melki.  Role of Different Alpha-Synuclein Strains in Synucleinopathies, Similarities with other Neurodegenerative Diseases , 2015, Journal of Parkinson's disease.

[64]  S. Sardi,et al.  Gaucher-related synucleinopathies: The examination of sporadic neurodegeneration from a rare (disease) angle , 2015, Progress in neurobiology.

[65]  V. Sossi,et al.  Phosphorylated α-synuclein in Parkinson’s disease: correlation depends on disease severity , 2015, Acta Neuropathologica Communications.

[66]  K. Walters,et al.  Prediagnostic presentations of Parkinson's disease in primary care: a case-control study , 2015, The Lancet Neurology.

[67]  H. Akiyama,et al.  Pathological alpha-synuclein propagates through neural networks , 2014, Acta neuropathologica communications.

[68]  Chuong B. Do,et al.  Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson’s disease , 2014, Nature Genetics.

[69]  D. Kirschner,et al.  A bacteriophage capsid protein provides a general amyloid interaction motif (GAIM) that binds and remodels misfolded protein assemblies. , 2014, Journal of molecular biology.

[70]  G. Halliday,et al.  Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson's disease. , 2014, Brain : a journal of neurology.

[71]  E. Bézard,et al.  Lewy body extracts from Parkinson disease brains trigger α‐synuclein pathology and neurodegeneration in mice and monkeys , 2014, Annals of neurology.

[72]  T. Foltynie,et al.  Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells , 2014, Brain : a journal of neurology.

[73]  L. Lannfelt,et al.  Immunotherapy targeting α-synuclein, with relevance for future treatment of Parkinson's disease and other Lewy body disorders. , 2014, Immunotherapy.

[74]  V. Lee,et al.  Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases , 2014, Nature Medicine.

[75]  He-Jin Lee,et al.  Extracellular α-synuclein—a novel and crucial factor in Lewy body diseases , 2014, Nature Reviews Neurology.

[76]  Jonas Christoffersson,et al.  Autophagy and apoptosis dysfunction in neurodegenerative disorders , 2014, Progress in Neurobiology.

[77]  G. Halliday,et al.  α-Synucleinopathy phenotypes. , 2014, Parkinsonism & related disorders.

[78]  C. Moussa,et al.  Nilotinib-induced autophagic changes increase endogenous parkin level and ubiquitination, leading to amyloid clearance , 2013, Journal of Molecular Medicine.

[79]  S. Prusiner,et al.  Transmission of multiple system atrophy prions to transgenic mice , 2013, Proceedings of the National Academy of Sciences.

[80]  B. Meier,et al.  Structural and functional characterization of two alpha-synuclein strains , 2013, Nature Communications.

[81]  R. Edwards,et al.  The Function of α-Synuclein , 2013, Neuron.

[82]  H. Lashuel,et al.  Alpha-synuclein Post-translational Modifications as Potential Biomarkers for Parkinson Disease and Other Synucleinopathies , 2013, Molecular & Cellular Proteomics.

[83]  C. Moussa,et al.  Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of α-synuclein in Parkinson's disease models. , 2013, Human molecular genetics.

[84]  Fabia Febbraro,et al.  Ser129D mutant alpha-synuclein induces earlier motor dysfunction while S129A results in distinctive pathology in a rat model of Parkinson's disease , 2013, Neurobiology of Disease.

[85]  F. Brodsky,et al.  Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds , 2013, Proceedings of the National Academy of Sciences.

[86]  Bin Zhang,et al.  Distinct α-Synuclein Strains Differentially Promote Tau Inclusions in Neurons , 2013, Cell.

[87]  L. Lannfelt,et al.  Monoclonal antibodies selective for α‐synuclein oligomers/protofibrils recognize brain pathology in Lewy body disorders and α‐synuclein transgenic mice with the disease‐causing A30P mutation , 2013, Journal of neurochemistry.

[88]  Bruno Vellas,et al.  Designing drug trials for Alzheimer’s disease: What we have learned from the release of the phase III antibody trials: A report from the EU/US/CTAD Task Force , 2013, Alzheimer's & Dementia.

[89]  A. Björklund,et al.  TFEB: Pathogenic role and therapeutic target in Parkinson disease. , 2013, Autophagy.

[90]  A. Rana,et al.  Alpha-Synuclein Induces Lysosomal Rupture and Cathepsin Dependent Reactive Oxygen Species Following Endocytosis , 2013, PloS one.

[91]  Anders Björklund,et al.  TFEB-mediated autophagy rescues midbrain dopamine neurons from α-synuclein toxicity , 2013, Proceedings of the National Academy of Sciences.

[92]  B. Mollenhauer,et al.  Total CSF α-synuclein is lower in de novo Parkinson patients than in healthy subjects , 2013, Neuroscience Letters.

[93]  T. Outeiro,et al.  Limelight on alpha-synuclein: pathological and mechanistic implications in neurodegeneration. , 2013, Journal of Parkinson's disease.

[94]  J. Kordower,et al.  Can intrabodies serve as neuroprotective therapies for Parkinson's disease? Beginning thoughts. , 2013, Journal of Parkinson's disease.

[95]  E. Masliah,et al.  Lentivirus mediated delivery of neurosin promotes clearance of wild-type α-synuclein and reduces the pathology in an α-synuclein model of LBD. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[96]  M. Frasier,et al.  α-synuclein imaging: a critical need for Parkinson's disease research. , 2013, Journal of Parkinson's disease.

[97]  N. Kanaan,et al.  Loss of Functional Alpha-Synuclein: A Toxic Event in Parkinson’s Disease? , 2016, Journal of Parkinson's disease.

[98]  A. Björklund,et al.  α-Synuclein–Induced Down-Regulation of Nurr1 Disrupts GDNF Signaling in Nigral Dopamine Neurons , 2012, Science Translational Medicine.

[99]  DelindaA . Johnson,et al.  Microglial Activation and Antioxidant Responses Induced by the Parkinson’s Disease Protein α-Synuclein , 2012, Journal of Neuroimmune Pharmacology.

[100]  D. D. Di Monte,et al.  Increased α-synuclein phosphorylation and nitration in the aging primate substantia nigra , 2012, Cell Death and Disease.

[101]  W. Oertel,et al.  Identifying prodromal Parkinson's disease: Pre‐Motor disorders in Parkinson's disease , 2012, Movement disorders : official journal of the Movement Disorder Society.

[102]  Bernard Schneider,et al.  α-Synuclein in Central Nervous System and from Erythrocytes, Mammalian Cells, and Escherichia coli Exists Predominantly as Disordered Monomer* , 2012, The Journal of Biological Chemistry.

[103]  A. Björklund,et al.  Impaired neurotransmission caused by overexpression of α-synuclein in nigral dopamine neurons , 2012, Proceedings of the National Academy of Sciences.

[104]  E. Masliah,et al.  The many faces of α-synuclein: from structure and toxicity to therapeutic target , 2012, Nature Reviews Neuroscience.

[105]  D. Selkoe,et al.  α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation , 2011, Nature.

[106]  D. Dickson,et al.  Neuropathology underlying clinical variability in patients with synucleinopathies , 2011, Acta Neuropathologica.

[107]  J. Stockman.  Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease , 2011 .

[108]  C. Dobson,et al.  Structure and properties of a complex of α-synuclein and a single-domain camelid antibody. , 2010, Journal of molecular biology.

[109]  J. Henderson,et al.  α-Synuclein Suppression by Targeted Small Interfering RNA in the Primate Substantia Nigra , 2010, PloS one.

[110]  R. Mandel,et al.  In vivo RNAi-mediated alpha-synuclein silencing induces nigrostriatal degeneration. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[111]  E. Masliah,et al.  Beclin 1 Gene Transfer Activates Autophagy and Ameliorates the Neurodegenerative Pathology in α-Synuclein Models of Parkinson's and Lewy Body Diseases , 2009, The Journal of Neuroscience.

[112]  M. Nalls,et al.  Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. , 2009, The New England journal of medicine.

[113]  H. Gendelman,et al.  Nitrated α-Synuclein-Induced Alterations in Microglial Immunity Are Regulated by CD4+ T Cell Subsets1 , 2009, The Journal of Immunology.

[114]  M. Cookson.  α-Synuclein and neuronal cell death , 2009, Molecular Neurodegeneration.

[115]  M. Farrer,et al.  In vivo silencing of alpha-synuclein using naked siRNA , 2008, Molecular neurodegeneration.

[116]  J. Trojanowski,et al.  Neuroinflammation and Oxidation/Nitration of α-Synuclein Linked to Dopaminergic Neurodegeneration , 2008, The Journal of Neuroscience.

[117]  R. Barbour,et al.  Red Blood Cells Are the Major Source of Alpha-Synuclein in Blood , 2008, Neurodegenerative Diseases.

[118]  H. Shill,et al.  Olfactory bulb α-synucleinopathy has high specificity and sensitivity for Lewy body disorders , 2008, Acta Neuropathologica.

[119]  Julia Thom Oxford,et al.  Calpain-Cleavage of α-Synuclein : Connecting Proteolytic Processing to Disease-Linked Aggregation , 2007 .

[120]  D. Rubinsztein,et al.  Trehalose, a Novel mTOR-independent Autophagy Enhancer, Accelerates the Clearance of Mutant Huntingtin and α-Synuclein* , 2007, Journal of Biological Chemistry.

[121]  Michael L. Kramer,et al.  Presynaptic α-Synuclein Aggregates, Not Lewy Bodies, Cause Neurodegeneration in Dementia with Lewy Bodies , 2007, The Journal of Neuroscience.

[122]  J. Kordower,et al.  Age-associated increases of α-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease? , 2007, Neurobiology of Disease.

[123]  Michael L. Kramer,et al.  Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. , 2007, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[124]  E. Masliah,et al.  Calpain-cleavage of alpha-synuclein: connecting proteolytic processing to disease-linked aggregation. , 2007, The American journal of pathology.

[125]  M. K. Sapru,et al.  Silencing of human α-synuclein in vitro and in rat brain using lentiviral-mediated RNAi , 2006, Experimental Neurology.

[126]  M. C. Bohn,et al.  Silencing of human alpha-synuclein in vitro and in rat brain using lentiviral-mediated RNAi. , 2006, Experimental neurology.

[127]  Jochen Klucken,et al.  Hsp70 Reduces α-Synuclein Aggregation and Toxicity* , 2004, Journal of Biological Chemistry.

[128]  B. Hyman,et al.  Hsp70 Reduces alpha-Synuclein Aggregation and Toxicity. , 2004, The Journal of biological chemistry.

[129]  Nutan Sharma,et al.  TorsinA and heat shock proteins act as molecular chaperones: suppression of α‐synuclein aggregation , 2002, Journal of neurochemistry.

[130]  J. Juillard,et al.  [Parkinson disease]. , 1985, Revue de l'infirmiere.